Endothelial Microparticle as an early Marker of Endothelial Dysfunction in Patients with Essential Hypertension: A Pilot Study

  • Santhi SilambananEmail author
  • R. S. Hermes
  • Emmanuel Bhaskar
  • Sri Gayathri
Short Communication


Hypertension is a global health burden causing immense morbidity and mortality especially from the complications of end-organ damage. It is expected to affect 29% of the population by the year 2025. Hypertension is usually asymptomatic; it is diagnosed by a disease of exclusion. Numerous factors such as inflammation, oxidative stress, genetic predisposition etc. play roles in the pathogenesis of hypertension. Endothelial microparticles (EMPs) are released into the circulation with the onset of changes in endothelium, even before the release of other routine vascular endothelial markers. EMPs mediate inflammation, thrombosis and vasoconstriction of blood vessels in hypertensives. This pilot study was undertaken to assess whether EMPs are early markers of endothelial dysfunction in essential hypertensive patients. The study was conducted as a large case control study in which 525 individuals were involved. It consisted of three study groups: Group I: individuals with normal blood pressure (JNC8), group II: hypertensives without evidence of end-organ damage and group III: hypertensives with evidence of end-organ damage. Homocysteine, hsCRP, fibrinogen, eNOS, oxLDL and other markers were measured. For analysis of EMPs a subset of individuals are taken from each group. Control group of 10 individuals who had homocysteine level more than15μmol/L was taken as Group I. Another 10 individuals were taken randomly of five each from groups II and III. EMPs were analyzed by flow cytometry and were identified as CD31 +, CD42 − microparticles with diameters < 1.0 mm. There was significant increase in EMPs (p = 0.035) in hypertensive individuals with end organ damage. Measurement of EMPs in hypertensive individuals could help physicians in identifying and initiating therapeutic interventions at a very early stage of the disease, thus improving the quality of life.


Hypertension Biomarkers of endothelium Endothelial dysfunction Endothelial microparticles Flow cytometry Homocysteine Atherosclerosis Endothelial injury Endorgan damage 



Endothelial microparticles


Endothelial nitric oxide synthase


Oxidized low density lipoprotein


High sensitive C-reactive protein


Median fluorescence intensity


Tissue factor


Tumor necrosis factor alpha


Plasminogen activator inhibitor-1




Reactive oxygen species



An oral presentation was done titled “Endothelial Microparticles as a marker of Endothelial Dysfunction in patients with Essential Hypertension” in AMBICON 2017—National conference held at Mysuru, by the Association of Medical Biochemists of India, from 17-11-2017 to 19-11-2017. The authors acknowledge Dr. Sathiasekaran, Professor in Community Medicine for his contribution in designing the study and analyzing the results.

Authors’ contributions

Hermes analyzed the samples for estimating biomarkers, Sri Gayathri helped in assessing endothelial microparticles by flow cytometry, Santhi Silambanan and Emmanuel Bhaskar were involved in writing the manuscript. All authors read and approved the final manuscript.


The work has been partly funded by Shri NPV Ramasamy Udayar Chancellor Research Fellowship. This fund was utilized for analysis of biological samples obtained from the participants.

Compliance with ethical standards

Conflict of interest

Santhi Silambanan was the brain behind this research and guided Hermes in conducting this research, which is in continuation of her Ph.D. work. Hermes has received the fund Shri NPV Ramasamy Udayar Chancellor Research Fellowship which supported part of this research. Emmanuel Bhaskar was a member of the research advisory committee, whose advice contributed to the results and discussion of the article. Sri Gayathri helped in doing the analysis of EMPs by flow cytometry in Central Research Facility of our Institute. The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

This study has been carried out in accordance with the Declaration of Helsinki and ethics clearance was obtained from Institutional Ethics Committee (IEC-NI/14/JUN/40/35). Written informed consent was obtained from the participants before being enrolled in the study. Only participants who volunteered to take part in the study were included.


  1. 1.
    Ivak P, Pitha J, Netuka I. Circulating microparticles as a predictor of vascular properties in patients on mechanical circulatory support; hype or hope? Physiol Res. 2016;65:727–35.PubMedGoogle Scholar
  2. 2.
    Lu Y, Li L, Yan HY, Su Q, Huang J, Fu C. Endothelial microparticles exert differential effects on functions of Th1 in patients with acute coronary syndrome. Int J Cardiol. 2013;168:5396–404.CrossRefGoogle Scholar
  3. 3.
    Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41:211–7.CrossRefGoogle Scholar
  4. 4.
    Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007;5:2445–52.CrossRefGoogle Scholar
  5. 5.
    Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost. 2005;3:1301–8.CrossRefGoogle Scholar
  6. 6.
    Liaw PC, Neuenschwander PF, Smirnov MD, Esmon CT. Mechanisms by which solubleendothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem. 2000;275:5447–52.CrossRefGoogle Scholar
  7. 7.
    Alkhatatbeh MJ, Enjeti AK, Baqar S, Ekinci E, Liu D, Thorne RF, Lincz LF. Strategies for enumeration of circulating microvesicles on a conventional flow cytometer: counting beads and scatter parameters. J Circ Biomark. 2018;7:1–10.CrossRefGoogle Scholar
  8. 8.
    Bartoloni E, Alunno A, Bistoni O, Caterbi S, Luccioli F, Santoboni G, et al. Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren’s syndrome: new markers of chronic endothelial damage? Rheumatology. 2015;54:536–44.CrossRefGoogle Scholar
  9. 9.
    Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31:27–33.CrossRefGoogle Scholar
  10. 10.
    Sekula M, Janawa G, Stankiewicz E, Stepien E. Endothelial microparticle formation in moderate concentrations of homocysteine and methionine in vitro. Cell Mol Biol Lett. 2011;16:69–78.CrossRefGoogle Scholar
  11. 11.
    Curtis AM, Edelberg J, Jonas R, Rogers WT, Moore JS, Syed W, et al. Endothelial microparticles: sophisticated vesicles modulating vascular function. Vasc Med. 2013;18:204–14.CrossRefGoogle Scholar
  12. 12.
    Karaouzene N, Merzouk H, Merzouk AS, Bouanane S, Loudjedi L, Merzouk SA. Interrelations between inflammatory and oxidative stress biomarkers in obese women with two complications (hypertension, diabetes). Rom J Diab Nutr Metab Dis. 2019;26(2):129–43.Google Scholar
  13. 13.
    França CN, Izar MCO, Amaral JB, Tegani DM, Fonseca FAH. Microparticles as potential biomarkers of cardiovascular disease. Arq Bras Cardiol. 2015;104:169–74.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Schiro A, Wilkinson FL, Weston R, Smyth JV, Serracino-Inglott F, Alexander MY, et al. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis. 2014;234:295–302.CrossRefGoogle Scholar
  15. 15.
    Berezin AE. Impaired phenotype of circulating endothelial-derived microparticles: novel marker of cardiovascular risk. J Cardiol Ther. 2015;2:365–70.CrossRefGoogle Scholar
  16. 16.
    Devaraj S, Kumaresan PR, Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem. 2011;57:1757–61.CrossRefGoogle Scholar
  17. 17.
    Mikirova N, Casciari J, Hunninghake R, Riordan N. Increased level of circulating endothelial microparticles and cardiovascular risk factors. J Clin Exp Cardiol. 2011;2:2–4.CrossRefGoogle Scholar
  18. 18.
    Amabile N, Guérin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol. 2005;16:3381–8.CrossRefGoogle Scholar
  19. 19.
    Paudel KR, Panth N, Kim D-W. Circulating endothelial microparticles: a key hallmark of atherosclerosis progression. Scientifica (Cairo). 2016;2016:1–9.CrossRefGoogle Scholar
  20. 20.
    Helbing T, Olivier C, Bode C, Moser M, Diehl P. Role of microparticles in endothelial dysfunction and arterial hypertension. World J Cardiol. 2014;6:1135–9.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2019

Authors and Affiliations

  1. 1.Department of BiochemistrySri Ramachandra Institute of Higher Education and Research (Deemed to be University)PorurIndia
  2. 2.Department of General Medicine, Sri Ramachandra Institute of Higher Education and ResearchPorurIndia
  3. 3.Department of Pathology, Sri Ramachandra Institute of Higher Education and ResearchPorurIndia

Personalised recommendations